Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0H2SY
|
||||
Former ID |
DAP001231
|
||||
Drug Name |
Oxybuprocaine
|
||||
Synonyms |
Benoxil; Benoxinate; Butoxyaminobenzoyldiethylaminoethanol; Butoxyprocaine; Conjucain; Dorsacain; Novescine; Novesinol; Oxibuprocaina; Oxibuprocainum; Oxibuprokain; Oxybucaine; Oxybuprocainum; Oxyriprocaine; Prescaina; Benoxinate hydrochloride; Monofree oxybuprocaine; Oxybuprocaine HCL; Oxybuprocaine hydrochloride; S 749;Monofree oxybuprocaine (TN); Novesin (TN); Novesine (TN); Oxibuprocaina [INN-Spanish]; Oxybuprocaine (INN); Oxybuprocaine [INN:BAN]; Oxybuprocainum [INN-Latin]; Diethylaminoethyl-4-amino-3-butoxybenzoate; BENZOIC ACID, 4-AMINO-3-BUTOXY-, 2-(DIETHYLAMINO)ETHYL ESTER; Benzoic acid, 4-amino-3-butoxy-, 2-(diethylamino)ethyl ester (7CI,8CI,9CI); 2-(Diethylamino)ethyl 4-amino-3-butoxybenzoate; 2-(diethylamino)ethyl 4-amino-3-n-butoxybenzoate; 2-Diethylaminoethyl 4-amino-3-butoxybenzoate; 3-Butoxy-4-aminobenzoic acid 2-(diethylamino)ethyl ester; 3-Butoxy-4-aminobenzoic acid 2-diethylaminoethyl ester; 4-Amino-3-butoxy-2-(diethylamino)ethyl ester benzoic acid; 4-Amino-3-butoxy-benzoic acid 2-diethylamino-ethyl ester; 4-Amino-3-butoxybenzoic acid 2-(diethylamino)ethyl ester; 4-Amino-3-butoxybenzoicacid 2-diethylaminoethyl ester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester; 4-Amino-3-n-butoxy-benzoesaeure-diaethylaminoaethylester [German]
|
||||
Drug Type |
Small molecular drug
|
||||
Therapeutic Class |
Anesthetics
|
||||
Company |
Norvatis Phamaceuticals Corporation
|
||||
Structure |
Download2D MOL |
||||
Formula |
C17H28N2O3
|
||||
InChI |
InChI=1S/C17H28N2O3/c1-4-7-11-21-16-13-14(8-9-15(16)18)17(20)22-12-10-19(5-2)6-3/h8-9,13H,4-7,10-12,18H2,1-3H3
|
||||
InChIKey |
CMHHMUWAYWTMGS-UHFFFAOYSA-N
|
||||
CAS Number |
CAS 99-43-4
|
||||
PubChem Compound ID | |||||
PubChem Substance ID |
841051, 5214240, 7980227, 8152845, 10539122, 11112575, 11466085, 11467205, 11485870, 14874159, 29223722, 46505399, 47365374, 47662470, 48259426, 48334674, 49698325, 49885584, 50100491, 50224342, 56320722, 56323957, 57322365, 85501766, 85787520, 96025006, 99245743, 103358745, 104306973, 117714298, 118312930, 123081044, 124801263, 125354048, 127645893, 131740430, 134224387, 134338470, 134971742, 137006537, 141665384, 143438151, 144040677, 160964232, 171578509, 175268839, 175442353, 178103700, 178125676, 179225186
|
||||
SuperDrug ATC ID |
D04AB03; S01HA02
|
||||
SuperDrug CAS ID |
cas=000099434
|
||||
Target and Pathway | |||||
Target(s) | Sodium channel | Target Info | Blocker | [537300] | |
KEGG Pathway | Dopaminergic synapse | ||||
Reactome | Interaction between L1 and Ankyrins | ||||
References | |||||
Ref 542131 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7123). | ||||
Ref 550739 | Drug information of Oxybuprocaine, 2008. eduDrugs. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.